 |
인쇄하기
취소
|
Kolon Life Science to go public
Kolon Life Science, Inc. (KLS), a subsidiary company of Kolon Group, is in the process of stepping into the secondary stock market Kosdaq.
The company is scheduled to sell 720,000 shares in its public offerings to attract investment and improve its corporate governance structure. Around 17 billion won is estimated to be raised.
KLS is aimed to achieve 842 billion won in annual sales by 20...
The company is scheduled to sell 720,000 shares in its public offerings to attract investment and improve its corporate governance structure. Around 17 billion won is estimated to be raised.
KLS is aimed to achieve 842 billion won in annual sales by 20...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.